London Cancer ALL guidelines
|
|
- Felicity Terry
- 5 years ago
- Views:
Transcription
1 London Cancer ALL guidelines Page 1 of 7
2 CONTENTS OVERVIEW - main points in ALL management... 3 AGE-SPECIFIC THERAPEUTIC APPROACHES... 4 SPECIFIC THERAPEUTIC PROBLEMS... 5 SUPPORTIVE CARE... 6 PATIENTS NOT WISHING TO ENTER CLINICAL TRIALS... 7 Page 2 of 7
3 Overview - main points in ALL management ALL GUIDELINES Adele Fielding Royal Free London NHST Rachael Hough UCLH NHST Asim Khwaja UCLH NHST Biju Krishnan Queens Hospital Romford Matthew Smith Barts and The London NHST 1. ALL is an eminently curable disease in young patients that becomes harder to treat with age - less patients are cured as age advances and therapeutic complications are increasingly common. 2. All patients should be treated with age-appropriate therapy. 3. Since the disease is rare, treatment is complicated and there are many areas of controversywhere best practice is not defined, patients should be treated within a clinical trial wherever possible. 4. Experienced specific and supportive care is required; a European Working Group on Adult ALL recommendation suggests that patients should be treated in centres which see at least five new patients per annum. 5 Adherence to the detail and timing of scheduled schemes of treatment is important. Minimising therapeutic delays positively impacts outcome. Recognising complications of therapy quickly and being aware which complications require treatment cessation and which do not is vital. 6. Allogeneic bone marrow transplant is currently a common element of patient management for patients aged 25 years and over. Hence, all patients and siblings aged 25 and older should be tissue-typed at diagnosis and an unrelated donor search carried out if there are no sibling donors. In practice, this means informing the appropriate Transplant Centre at diagnosis about all age-appropriate new diagnoses of ALL. Currently, those aged between 25 and 65 years old and all patients who are Ph+ should be considered as possible transplant candidates at diagnosis. 7. Appropriate specimens should always be taken before therapy is started. Cytogenetic testing is standard of care, Minimal Residual Disease assessment is also now standard practice. This requires a diagnostic specimen to be sent centrally to the Adult MRD Laboratory at the Royal Free Hospital (for UKALL14, 60+ MARALL), Molecular Haematology at the Royal London Hospital (for BLT patients not on study) or Paediatric MRD laboratory at GOSH (for UKALL2011), in order to identify patient-specific markers at diagnosis. 8. Clinical trials currently open within the Network are listed in red typeface Page 3 of 7
4 AGE-SPECIFIC THERAPEUTIC APPROACHES 1. Patients aged years. Patients aged 0-18 years should be referred to the joint primary treatment centre (UCLH/GOS) and patients aged years should be offered treatment at UCLH or a local TYA designated centre. Patients aged less than 25 years should be offered the opportunity enter UKALL2011. UKALL2011 does not accommodate patients with Philadelphia positive (Ph+) disease. Hence, if patients of this age group have Ph+ disease they need to receive imatinib as soon as possible and they must be considered for allogeneic transplant. Such patients are eligible for entry UKALL14 in which the lower age limit for patients with Ph+ALL is 18 years. Younger patients should be offered entry into the ESPHALL study. 2. Patients aged years. Patients with both Ph- and Ph+ disease within this age group should be offered entry to UKALL14. Between the age of 60 and 65, some patients will not be considered suitable for intensive therapy and this should be assessed on a case by case basis. 3. Patients aged 65 and over and those aged 55 and over who are not fit for UKALL14. Patients should be offered the opportunity to enter UKALL60+. If trial entry is not acceptable patients should be treated according to age and clinical status. Ideally, patients should receive induction therapy of sufficient intensity to achieve complete remission. If patients can tolerate repeated cycles of inpatient chemotherapy, a reasonable approach would be to use two cycles of induction chemotherapy followed by one cycle of CNS directed prophylaxis with high dose Methotrexate dose dependent on renal function and patient performance status. If patients are not fit for consolidation therapy they should be placed directly onto maintenance therapy. All patients being treated with curative intent should receive at least six doses of Methotrexate intrathecally, if tolerated. A trial of the bi-specific antibody Blinotunamab (MT /BLAST) is available at the Royal Free Hospital for patients who are too old to enter UKALL14 and who have minimal residual disease at the end of three courses of intensive chemotherapy. MT is also compatible with UKALL60+ - patients who are MRD+ after intial treatment on UKALL60+ may be referred for MT The intensiveness of the chemotherapy is at the discretion of the Investigator. Patients with Philadelphia positive disease should receive Imatinib at a dose of 600 mgs per day orally, wherever tolerated. A combination of imatinib with a maintenance schedule might offer additional benefit but there are no good data to support this. Page 4 of 7
5 SPECIFIC THERAPEUTIC PROBLEMS 1. Relapsed ALL Relapsed ALL is a difficult therapeutic situation to manage. The treatment of any patient with relapse should bear in mind what the maximum potential benefit for the patient could be and balance this against the risk of treatment related morbidity and mortality. The only curative approach to the treatment of relapse is allogeneic bone marrow transplant. The achievement of a CR is a prerequisite for this. Patients with relapsed B precursor ALL should be offered the opportunity to enter a clinical trial. Patients less than18 years of age should be offered the R3 trial. Three studies for older patients with relapsed B-precursor ALL are presently available within the UK. Each trial has different entry criteria and may be valuable for different patient populations. It is possible for patients to cycle through more than one relapse trial, if this is clinically appropriate and desirable to the patient. -The MARALL (Monoclonal antibodies in relapsed ALL) Trial for relapsed B precursor ALL which is open at Barts, UCLH and the Royal Free Hospital. The trial combines a less aggressive re-induction schedule in combination with 2 anti-b cell monoclonal antibodies. -MT (Royal Free) offers patients with relapsed ALL the opportunity to receive Blinatumomab -Pfizer B offers patients with relapsed ALL the opportunity to receive either chemotherapy or inotuzumab ozogamicin in a randomised manner. The table below summarises some of the main characteristics of the relapse trials. Trial Design Age Chemotherapy Ph status LFT MARALL Single arm 16+ Vinc/Pred/L-asp or Any <2.5 x ULN Vinc/Pred no L-asp for older patients Can be given as out patient MT Single arm 18+ None blinatumomab only, 24hr inf. Can be given as out patient Ph neg only <5 x ULN Bili <1.5 x ULN B Randomised phase RCT Inotuzumab ozogamicin vs. FLA- Ida or similar Would require in patient Ph neg only <2.5x ULN Bili <1.5 x ULN Page 5 of 7
6 Outside a trial, in some situations it may be appropriate to take a palliative approach. In other situations, aggressive re-induction therapy will be appropriate. It is clear that following relapse, patients who are younger and have had longer durations of first remission are more likely to do well and it is in these patients in whom the most aggressive approaches should be pursued. Allogeneic bone marrow transplantation is the only known curative therapy for relapsed ALL and aggressive approaches should have the overall aim of achieving complete remission so that the patient can receive a bone marrow transplant. If the patient has already received a bone marrow transplant a second transplant will rarely be appropriate and consideration should be given to entering Phase 1 and 2 trials of novel therapy. The rate of second complete remission is approximately 50%. There are no data to indicate the best choice of re-induction regimen. If patients are ineligible for, or do not wish to enter a trial, FLAG-IDA is a commonly used and appropriate choice of re-induction regimen for those who are fit. Nelarabine is licensed for the treatment of relapsed T-ALL. It is used as a single agent and is a reasonable choice for re-induction in these circucmstances. 2. Relapsed Philadelphia Positive ALL In the case of Ph+ disease, paradoxically, relapse may be easier to treat, at least in the short term. A specimen should be sent to determine whether there are any mutations in the BCR-ABL kinase domain (test can be carried out at Imperial College London or by the Wessex Genetics Service), to guide choice of subsequent TKI. p210 quantification is typically available locally. p190 quantification is available in the MRD laboratory at the Royal Free Hospital. Dasatinib should be offered to patients with relapsed Ph+ ALL where there is no contra-indicating mutation in the BCR- ABL KD. 3. Central nervous system relapse or other isolated extramedullary relapse Extramedullary relapse is invariably associated with subsequent bone marrow relapse even if the two are not concomitant. If treatment is with curative intent, systemic therapy needs to be give as well as local therapy. In the case of CNS relapse, intrathecal therapy should be given until blasts are no longer detectable in the CSF. The choice of agent depends upon the clinical situation, CNS irradiation is also an important component of therapy but should not be given in conjunction with MTX. For this reason cytarabine and steroid may be the appropriate choice immediately following CNS relapse. CNS irradiation carries a potential for cognitive impairment and this needs to be discussed with the patient, SUPPORTIVE CARE Supportive care is very important for all patients with ALL. There are many aspects to consider and they are carefully documented in UKALL2011 and UKALL14. These protocols are available for download and should be consulted for precise details of appropriate supportive care, even if patients are not entering the clinical trial. Page 6 of 7
7 PATIENTS NOT WISHING TO ENTER CLINICAL TRIALS All patients should be strongly encouraged to enter a clinical trial wherever possible, because of the rarity of the disease and the importance of gathering appropriate information in areas of controversy. Additionally, patients may benefit directly from entering clinical trials by receiving novel therapies. It is not appropriate that a patient is not offered treatment on a clinical trial simply because the trial is not open at the presenting centre. Patients should always be offered the opportunity to be referred to a centre where the appropriate clinical trial is open. It is strongly discouraged that the protocols described in clinical trials are followed without the patients entering the trial concerned. If patients do not wish to enter the currently available trials or their physicians think that these are inappropriate an individual treatment decision will need to be made taking into account the patients age, immunophenotype, cytogenetics and initial treatment response by minimal residual disease. Specific advice on individual patients who do not wish to enter clinical trials having had the opportunity to do so will gladly be provided by Dr Adele Fielding ( , a.fielding@ucl.ac.uk at the Royal Free Hospital. If Dr Fielding is unavailable, individual advice may be obtained from other members of the UK NCRI Adult ALL Group. Drs Rachel Hough (UCLH) and Clare Rowntree (Cardiff) can provide expert advice on the management of young adults and adolescents. Dr David Marks (Bristol) will provide expert advice on the treatment of adults with ALL and particularly issues relating to bone marrow transplantation. Dr Bella Patel (Royal Free Hospital) can provide expert advice on aspects of minimal residual disease. Dr Matthew Smith (St Bartholomew s Hospital) can provide expert advice on the treatment of relapsed ALL. Page 7 of 7
Acute Lymphoblastic Leukaemia Guidelines
Acute Lymphoblastic Leukaemia Guidelines Approved by Pathway Board for Haematological Malignancies Coordinating author: Adele Fielding, Royal Free London NHS Trust Date of issue: 12.03.2015 Version number:
More informationClinical Guidelines for Lymphoid Diseases Acute Lymphoblastic Leukaemia (ALL)
Clinical Guidelines for Lymphoid Diseases Acute Lymphoblastic Leukaemia (ALL) Reference Number Version Status Executive Lead(s) Name and Job Title Author(s) Name and Job Title 13-2H-107 8 Dr Helen Barker
More informationAcute Lymphoblastic Leukemia (ALL) Ryan Mattison, MD University of Wisconsin March 2, 2010
Acute Lymphoblastic Leukemia (ALL) Ryan Mattison, MD University of Wisconsin March 2, 2010 ALL Epidemiology 20% of new acute leukemia cases in adults 5200 new cases in 2007 Most are de novo Therapy-related
More informationSummary. Table 1 Blinatumomab administration, as per European marketing authorisation
Cost-effectiveness of blinatumomab (Blincyto ) for the treatment of relapsed or refractory B precursor Philadelphia chromosome negative acute lymphoblastic leukaemia in adults. The NCPE assessment of blinatumomab
More informationALL MAINTENANCE (25-60 years)
ALL MAINTENANCE (25-60 years) INDICATION Adult Acute Lymphoblastic Leukaemia (ALL) in remission not eligible for allogeneic transplantation This protocol is suitable for patients aged 25-60 years. It may
More informationAcute Lymphoblastic and Myeloid Leukemia
Acute Lymphoblastic and Myeloid Leukemia Pre- and Post-Disease Form Acute Lympoblastic Leukemia Mary Eapen MD, MS Acute Lymphoblastic Leukemia SEER Age-adjusted incidence rate 1.6 per 100,000 men and women
More informationForm 2011 R4.0: Acute Lymphoblastic Leukemia (ALL) Pre-HCT Data
Key Fields Sequence Number: Date Received: - - CIBMTR Center Number: CIBMTR Recipient ID: Date of HCT for which this form is being completed: - - HCT type: (check all that apply) Autologous Allogeneic,
More informationALL Phase 2 Induction (25-60 years)
ALL Phase 2 (25-60 years) INDICATION of remission in Adult Acute Lymphoblastic Leukaemia (ALL) patients This protocol is suitable for patients aged 25-60 years. It may sometimes be used in older patients
More informationManchester Cancer Haematological-Oncology Pathway Board. Guidelines for the Diagnosis and treatment of Adult Acute Lymphoblastic Leukaemia
Manchester Cancer Haematological-Oncology Pathway Board Guidelines for the Diagnosis and treatment of Adult Acute Lymphoblastic Leukaemia Coordinating author: Dr Anna Castleton Date of issue: June 2016
More informationKYMRIAH (tisagenlecleucel)
KYMRIAH (tisagenlecleucel) Non-Discrimination Statement and Multi-Language Interpreter Services information are located at the end of this document. Coverage for services, procedures, medical devices and
More informationCIBMTR Center Number: CIBMTR Recipient ID: Today s Date: Date of HSCT for which this form is being completed:
Chronic Myelogenous Leukemia (CML) Post-HSCT Data Sequence Number: Date Received: Registry Use Only Today s Date: Date of HSCT for which this form is being completed: HSCT type: autologous allogeneic,
More informationETP - Acute Lymphoblastic Leukaemia
ETP - Acute Lymphoblastic Leukaemia Dr Sally Campbell - Royal Children s Hospital Melbourne 24 February 2017 T-ALL 12-15% of all newly diagnosed ALL cases in pediatrics are T-ALL T-ALL behaves differently
More informationMANAGEMENT OF ACUTE LYMPHOBLASTIC LEUKEMIA. BY Dr SUBHASHINI 1 st yr PG DEPARTMENT OF PEDIATRICS
MANAGEMENT OF ACUTE LYMPHOBLASTIC LEUKEMIA BY Dr SUBHASHINI 1 st yr PG DEPARTMENT OF PEDIATRICS Introduction The management of ALL, the most common childhood malignancy (1/3 rd of all malignancy), has
More informationFAST FACTS Eligibility Reviewed and Verified By MD/DO/RN/LPN/CRA Date MD/DO/RN/LPN/CRA Date Consent Version Dated
Page 1 of 8 COG-AALL1131: A Phase III Randomized Trial for Newly Diagnosed High Risk B-Lymphoblastic Leukemia (B-ALL) Including a Stratum Evaluating Dasatinib (IND#73789, NSC#732517) in Patients with Ph-like
More informationN Engl J Med Volume 373(12): September 17, 2015
Review Article Acute Myeloid Leukemia Hartmut Döhner, M.D., Daniel J. Weisdorf, M.D., and Clara D. Bloomfield, M.D. N Engl J Med Volume 373(12):1136-1152 September 17, 2015 Acute Myeloid Leukemia Most
More informationTiming and complications of allogeneic stem cell transplant in Ph + ALL
Timing and complications of allogeneic stem cell transplant in Ph + ALL Dr Ashlea Campbell Haematology Advanced Trainee Concord Repatriation and General Hospital Royal Prince Alfred Hospital 24 th Feb
More informationNational Institute for Health and Care Excellence. Single Technology Appraisal (STA)
Single Technology Appraisal (STA) Gemtuzumab ozogamacin for untreated de novo acute myeloid leukaemia Response to consultee and commentator comments re-scope Please note: Comments received in the course
More informationFAST FACTS Eligibility Reviewed and Verified By MD/DO/RN/LPN/CRA Date MD/DO/RN/LPN/CRA Date Consent Version Dated
Page 1 of 6 COG-AALL1621, A Phase 2 Study of Inotuzumab Ozogamicin (NSC# 772518, IND#133494) in Children and Young Adults with Relapsed or Refractory CD22+ B-Acute Lymphoblastic Leukemia (B-ALL) FAST FACTS
More informationALL Phase 1 Induction (25-60 years)
ALL Phase 1 (25-60 years) INDICATION of remission in Adult Acute Lymphoblastic Leukaemia (ALL) patients This protocol is suitable for patients aged 25-60 years. It may sometimes be used in older patients
More informationIntroduction: Trial contacts: Trial Management Group (TMG):
Introduction: Cancer Research UK is supporting central coordination through the Cancer Research UK & UCL Cancer Trials Centre (UCL CTC) the coordinating centre for the trial. Problems relating to this
More informationUKALL14. A randomized trial for adults with newly diagnosed acute lymphoblastic leukaemia. Protocol version & date: Version
UKALL14 A randomized trial for adults with newly diagnosed acute lymphoblastic leukaemia Trial Sponsor: University College London Trial Sponsor no: UCL/08/0167 Trial funder: Cancer Research UK Funder reference:
More informationLeukemia. Andre C. Schuh. Princess Margaret Cancer Centre Toronto
Leukemia Andre C. Schuh Princess Margaret Cancer Centre Toronto AGENDA Ø Overview Ø Key News This Year Ø Key News out of ASH 2016 Sessions Abstracts Ø Canadian Perspective Ø Overview 2015- Stone, R. et
More informationPhiladelphia-positive Acute Lymphoblastic Leukemia
Philadelphia-positive Acute Lymphoblastic Leukemia Nicolas Boissel Service d Hématologie Unité Adolescents et Jeunes Adultes Hôpital Saint-Louis, Paris Ph+ acute lymphoblastic leukemia DR+, CD19+, CD22+,
More informationAppendix 6: Indications for adult allogeneic bone marrow transplant in New Zealand
Appendix 6: Indications for adult allogeneic bone marrow transplant in New Zealand This list provides indications for the majority of adult BMTs that are performed in New Zealand. A small number of BMTs
More informationAcute Leukaemia Quality Performance Indicators
Acute Leukaemia Quality Performance Indicators Patients diagnosed between July 2014 and June 2017 Publication date 19 June 2018 An Official Statistics publication for Scotland This is an Official Statistics
More informationNational Institute for Health and Care Excellence. Single Technology Appraisal (STA)
Single Technology Appraisal (STA) Tisagenlecleucel-T for previously treated B-cell acute lymphoblastic Response to consultee and commentator comments on the draft remit and draft scope (pre-referral) Please
More informationFinal Appraisal Report. ) for the treatment of T-cell acute lymphoblastic leukaemia and T-cell lymphoblastic lymphoma. GlaxoSmithKline UK
Final Appraisal Report Nelarabine (Atriance ) for the treatment of T-cell acute lymphoblastic leukaemia and T-cell lymphoblastic lymphoma GlaxoSmithKline UK Advice No: 0909 April 2009 Recommendation of
More information2011: ALL Pre-HCT. Subsequent Transplant
2011: ALL Pre-HCT The Acute Lymphoblastic Leukemia Pre-HCT Data Form is one of the Comprehensive Report Forms. This form captures ALL-specific pre-hct data such as: the recipient s hematologic and cytogenetic
More informationTRANSPARENCY COMMITTEE OPINION. 14 February 2007
The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 14 February 2007 GLIVEC 100 mg, capsule B/120 capsules (CIP: 358 493-5) GLIVEC 100 mg, capsule B/180 capsules (CIP:
More informationCurrent Strategies for Relapsed/Refractory ALL in AYAs and Adults: Where We Are Now
Current Strategies for Relapsed/Refractory ALL in AYAs and Adults: Where We Are Now Eunice S. Wang, MD Roswell Park Cancer Institute Buffalo, New York, United States Relapsed ALL Carries a Poor Prognosis
More informationHull and East Yorkshire and North Lincolnshire NHS Trusts Haematology Multidisciplinary Team Guideline and Pathway. Chronic Myeloid Leukaemia
Hull and East Yorkshire and North Lincolnshire NHS Trusts Haematology Multidisciplinary Team Guideline and Pathway Chronic Myeloid Leukaemia 1 BACKGROUND The Hull and North Lincolnshire Haematology Multidisciplinary
More informationImmunotherapies in Acute Lymphoblastic Leukaemia. Professor David Ritchie Royal Melbourne Hospital
Immunotherapies in Acute Lymphoblastic Leukaemia Professor David Ritchie Royal Melbourne Hospital Blinatumomab Cases Case 1: Mr BE 30 year old male Aged 17, diagnosed Philadelphia negative B-ALL in Nov
More informationSupplementary appendix
Supplementary appendix This appendix formed part of the original submission and has been peer reviewed. We post it as supplied by the authors. Supplement to: Biondi A, Schrappe M, De Lorenzo P, et al.
More informationHematopoietic Cell Transplantation for Acute Lymphoblastic Leukemia
Hematopoietic Cell Transplantation for Acute Lymphoblastic Leukemia Policy Number: 8.01.32 Last Review: 7/2018 Origination: 7/2002 Next Review: 7/2019 Policy Blue Cross and Blue Shield of Kansas City (Blue
More informationACUTE LYMPHOBLASTIC LEUKEMIA
ACUTE LYMPHOBLASTIC LEUKEMIA YOUNG ADULT PATIENT Highlights clonoseq Tracking (MRD) Testing in the peripheral blood revealed early signs of relapse post-transplant Patient achieved remission after CAR-T
More informationAcute myeloid leukemia: prognosis and treatment. Dimitri A. Breems, MD, PhD Internist-Hematoloog Ziekenhuis Netwerk Antwerpen Campus Stuivenberg
Acute myeloid leukemia: prognosis and treatment Dimitri A. Breems, MD, PhD Internist-Hematoloog Ziekenhuis Netwerk Antwerpen Campus Stuivenberg Patient Female, 39 years History: hypothyroidism Present:
More informationLeukemias. Prof. Mutti Ullah Khan Head of Department Medical Unit-II Holy Family Hospital Rawalpindi Medical College
Leukemias Prof. Mutti Ullah Khan Head of Department Medical Unit-II Holy Family Hospital Rawalpindi Medical College Introduction Leukaemias are malignant disorders of the haematopoietic stem cell compartment,
More informationSystemic Treatment of Acute Myeloid Leukemia (AML)
Guideline 12-9 REQUIRES UPDATING A Quality Initiative of the Program in Evidence-Based Care (PEBC), Cancer Care Ontario (CCO) Systemic Treatment of Acute Myeloid Leukemia (AML) Members of the Acute Leukemia
More informationPharmacotherapy for adult acute lymphoblastic leukemia: an update from recent clinical trials and future directions
Pharmacotherapy for adult acute lymphoblastic leukemia: an update from recent clinical trials and future directions Clin. Invest. (2012) 2(7), 715 731 In adults, acute lymphoblastic leukemia (ALL) is an
More informationClinical Management Guideline for Adult Acute Lymphoblastic Leukaemia
Clinical Management Guideline for Adult Acute Lymphoblastic Leukaemia UNCONTROLLED WHEN PRINTED NOSCAN Haematology MCN has agreed the information contained within this document to guide the management
More informationFirst relapsed childhood ALL Role of chemotherapy
First relapsed childhood ALL Role of chemotherapy Thirachit Chotsampancharoen, M.D. Division of Pediatric Hematology/Oncology Department of Pediatrics Prince of Songkla University Hat-Yai, Songkhla 25
More informationAbstract 861. Stein AS, Topp MS, Kantarjian H, Gökbuget N, Bargou R, Litzow M, Rambaldi A, Ribera J-M, Zhang A, Zimmerman Z, Forman SJ
Treatment with Anti-CD19 BiTE Blinatumomab in Adult Patients With Relapsed/Refractory B-Precursor Acute Lymphoblastic Leukemia (R/R ALL) Post-Allogeneic Hematopoietic Stem Cell Transplantation Abstract
More informationControversies in Hematology: Case-Based Discussion. Acute leukemia in Adolescents and Young adults October 2018, Chiang Mai Thailand
Controversies in Hematology: Case-Based Discussion Acute leukemia in Adolescents and Young adults 25-26 October 2018, Chiang Mai Thailand Associate Prof. Adisak Tantiworawit, MD Division of Hematology,
More informationPersonalized Therapy for Acute Myeloid Leukemia. Patrick Stiff MD Loyola University Medical Center
Personalized Therapy for Acute Myeloid Leukemia Patrick Stiff MD Loyola University Medical Center 708-327-3216 Major groups of Mutations in AML Targets for AML: Is this Achievable? Chronic Myeloid Leukemia:
More informationTesticular cancer and other germ cell tumours. London Cancer Jonathan Shamash
Testicular cancer and other germ cell tumours London Cancer 2018 Jonathan Shamash Background Testicular germ cell tumours are the commonest cancers of young men Overall they are curable but long term side
More informationCML TREATMENT GUIDELINES
CML TREATMENT GUIDELINES INITIAL INVESTIGATION Propose enrolment in the CML Registry of the CML-MPN Quebec Research Group. Medical history : Question for cardio-respiratory disorders, diabetes, pancreatitis,
More informationCuring Myeloma So Close and Yet So Far! Luciano J. Costa, MD, PhD Associate Professor of Medicine University of Alabama at Birmingham
Curing Myeloma So Close and Yet So Far! Luciano J. Costa, MD, PhD Associate Professor of Medicine University of Alabama at Birmingham What is cure after all? Getting rid of it? Stopping treatment without
More informationAML 17 Protocol Amendments: Version 7.2 June 2012 to version 8.0 October 2012
AML 17 Protocol Amendments: Version 7.2 June 2012 to version 8.0 October 2012 Section Original Change Page 1 The trial is open to all patients aged less than 60 years, whether adults or children, and also
More informationMedical Research Council Acute Lymphoblastic Leukaemia Trial XII (UKALL XII) Version 4.1 February 2006
Medical Research Council Acute Lymphoblastic Leukaemia Trial XII (UKALL XII) Version 4.1 February 2006 Medical Research Council Working Party on Leukaemia in Adults Joint Trial with Eastern Cooperative
More informationPDF of Trial CTRI Website URL -
Clinical Trial Details (PDF Generation Date :- Wed, 19 Dec 2018 02:45:15 GMT) CTRI Number Last Modified On 25/12/2017 Post Graduate Thesis Type of Trial Type of Study Study Design Public Title of Study
More informationSingle Technology Appraisal (STA) Arsenic trioxide for treating acute promyelocytic leukaemia
Single Technology Appraisal (STA) Arsenic trioxide for treating acute promyelocytic leukaemia Response to consultee and commentator comments on the draft remit and draft scope (pre-referral) Please note:
More informationCorporate Medical Policy
Corporate Medical Policy Hematopoietic Stem-Cell Transplantation for Acute Myeloid File Name: Origination: Last CAP Review: Next CAP Review: Last Review: hematopoietic_stem-cell_transplant_for_acute_myeloid_leukemia
More informationSingle Technology Appraisal (STA) Midostaurin for untreated acute myeloid leukaemia
Single Technology Appraisal (STA) Midostaurin for untreated acute myeloid leukaemia Response to consultee and commentator comments on the draft remit and draft scope (pre-referral) Please note: Comments
More informationThe probability of curing children with acute. brief report
brief report Hematopoietic stem cell transplant versus chemotherapy plus tyrosine kinase inhibitor in the treatment of pediatric Philadelphia chromosome-positive acute lymphoblastic leukemia (ALL) Khadra
More informationAdult T-cell lymphoblastic leukemia/lymphoma. Lymphoma Tumor Board. September 8, 2017
Adult T-cell lymphoblastic leukemia/lymphoma Lymphoma Tumor Board September 8, 2017 Diagnosis of T-cell lymphoblastic leukemia/lymphoma Lymphoblastic lymphoma (LBL) is rare Sub-type of lymphoma that is
More informationSPECIAL AUTHORIZATION REQUEST FOR COVERAGE OF HIGH COST CANCER DRUGS
SPECIAL AUTHORIZATION REQUEST FOR COVERAGE OF HIGH COST CANCER DRUGS (Filgrastim, Capecitabine, Imatinib, Dasatinib, Erolotinib, Sunitinib, Pazopanib, Fludarabine, Sorafenib, Crizotinib, Tretinoin, Nilotinib,
More informationPAX5-JAK2 fusion in acute lymphoblastic leukaemia. Dr Andrew Baldi Royal Children s Hospital 24 February 2017 Melbourne
PAX5-JAK2 fusion in acute lymphoblastic leukaemia Dr Andrew Baldi Royal Children s Hospital 24 February 2017 Melbourne Case 12-year-old girl Diagnosed with BCP ALL in November 2015 Presenting WCC 35x10
More informationpan-canadian Oncology Drug Review Final Clinical Guidance Report Blinatumomab (Blincyto) Resubmission for Acute Lymphoblastic Leukemia
pan-canadian Oncology Drug Review Final Clinical Guidance Report Blinatumomab (Blincyto) Resubmission for Acute Lymphoblastic Leukemia August 31, 2017 DISCLAIMER Not a Substitute for Professional Advice
More informationInotuzumab Ozogamicin in ALL. Hagop Kantarjian M.D. May 2016 Bologna, Italy
Inotuzumab Ozogamicin in ALL Hagop Kantarjian M.D. May 2016 Bologna, Italy Immuno Oncology in ALL Monoclonals + cytotoxic agents e.g.inotuzumab Bispecific monoclonals (CD3 + CD19) e.g.blinatumomab Modified
More information: Prepublished online July 23, 2010; doi: /blood
Adele K. Fielding 2010 116: 3409-3417 Prepublished online July 23, 2010; doi:10.1182/blood-2010-01-242750 How I treat Philadelphia chromosome positive acute lymphoblastic leukemia Updated information and
More informationMr. John Walter Thank you, Lauren. I d like to add my welcome to the patients, caregivers, and healthcare professionals on the program today.
Slide 1 Welcome and Introductions Operator Good afternoon, and welcome to ALL: Understanding Diagnosis & Treatment for Adults, a free telephone web education program. It is my pleasure to introduce your
More informationALL CONSOLIDATION- Cycle 3 (25-60 years)
ALL CONSOLIDATION- (25-60 years) INDICATION Adult Acute Lymphoblastic Leukaemia (ALL) in remission not eligible for allogeneic transplantation This protocol is suitable for patients aged 25-60 years. It
More informationTechnology appraisal guidance Published: 24 August 2016 nice.org.uk/guidance/ta401
Bosutinib for previously treated chronic myeloid leukaemia Technology appraisal guidance Published: 24 August 2016 nice.org.uk/guidance/ta401 NICE 2018. All rights reserved. Subject to Notice of rights
More informationInstructions for Chronic Lymphocytic Leukemia Post-HSCT Data (Form 2113)
Instructions for Chronic Lymphocytic Leukemia Post-HSCT Data (Form 2113) This section of the CIBMTR Forms Instruction Manual is intended to be a resource for completing the CLL Post-HSCT Data Form. E-mail
More informationALL-RELAPSE GROUP Päivi Lähteenmäki on behalf of the group
ALL-RELAPSE GROUP 18.11.2014 Päivi Lähteenmäki on behalf of the group Meeting in Bergen and 2 telephone meetings (Sept, Oct) IntReALL-group in Lissabon (September, Thomas F) IntReALL SR : Denmark has registered
More informationUnderstanding Treatment-Free Remission and How It Impacts You
Understanding Treatment-Free Remission and How It Impacts You Written by Michael J. Mauro, M.D. Leader, Myeloproliferative Disorders Program Memorial Sloan Kettering Cancer Center Professor of Medicine,
More informationscreening procedures Disease resistant to full-dose imatinib ( 600 mg/day) or intolerant to any dose of imatinib
Table S1. Study inclusion and exclusion criteria Inclusion criteria Aged 18 years Signed and dated informed consent form prior to protocol-specific screening procedures Cytogenetic- or PCR-based diagnosis
More informationManagement of Acute Lymphoblastic Leukemia
Management of Acute Lymphoblastic Leukemia Joseph C. Alvarnas, MD City of Hope Comprehensive Cancer Center Acute Lymphoblastic Leukemia (ALL) Approximately 6,000 patients per year diagnosed with ALL 60%
More informationBlood Cancers. Blood Cells. Blood Cancers: Progress and Promise. Bone Marrow and Blood. Lymph Nodes and Spleen
Blood Cancers: Progress and Promise Mike Barnett & Khaled Ramadan Division of Hematology Department of Medicine Providence Health Care & UBC Blood Cancers Significant health problem Arise from normal cells
More informationElisabeth Koller 3rd Medical Dept., Center for Hematology and Oncology, Hanusch Hospital, Vienna, Austria
Elisabeth Koller 3rd Medical Dept., Center for Hematology and Oncology, Hanusch Hospital, Vienna, Austria Incidence Diagnosis Prognostic factors Treatment Induction therapy - HSCT Indications for HSCT
More informationAdult ALL: NILG experience
Adult ALL: NILG experience R Bassan USC Ematologia, Ospedali Riuniti, Bergamo SIE Interregionale, Padova 12 5 2011 Now and then Northern Italy Leukemia Group 2000-10 Prospective clinical trials 09/00 10/07
More informationCorrelation of Sex and Remission of Acute Lymphoblastic Leukemia-L1 (ALL-L1) in Children
International Journal of Clinical and Experimental Medical Sciences 2015; 1(2): 11-15 Published online July 6, 2015 (http://www.sciencepublishinggroup.com/j/ijcems) doi: 10.11648/j.ijcems.20150102.12 Correlation
More informationRelapsed acute lymphoblastic leukemia. Lymphoma Tumor Board. July 21, 2017
Relapsed acute lymphoblastic leukemia Lymphoma Tumor Board July 21, 2017 Diagnosis - Adult Acute Lymphoblastic Leukemia (ALL) Symptoms/signs include: Fever Increased risk of infection (especially bacterial
More informationTRANSPARENCY COMMITTE OPINION. 19 December 2007
The legally binding text is the original French version TRANSPARENCY COMMITTE OPINION 19 December 2007 ATRIANCE 5 mg/ml, Solution for Infusion Pack of 6 vials (571 348-9) Applicant: GlaxoSmithKline nelarabine
More informationSwiss Summary of the Risk Management Plan (RMP) for BLINCYTO (Blinatumomab)
Swiss Summary of the Risk Management Plan (RMP) for BLINCYTO (Blinatumomab) RMP Summary: Version 1, April 2017 EU RMP: Version 3.2, November 2016 Page 1 of 13 The Risk Management Plan (RMP) is a comprehensive
More informationCan ALL be managed without chemotherapy/transplant? (Position: NO) D.Hoelzer J.W.Goethe University Frankfurt
Can ALL be managed without chemotherapy/transplant? (Position: NO) D.Hoelzer J.W.Goethe University Frankfurt Barcelona, September 2012 First report of Monotherapy in childhood ALL 10/16 children with acute
More informationHSCT for Myeloproliferative Disorders. Jane Apperley
HSCT for Myeloproliferative Disorders Jane Apperley Myeloproliferative disorders CML Polycythemia vera Essential thrombocythemia Primary myelofibrosis bcr-abl + bcr-abl - JAK2 (valine to phenylalanin an
More informationFLAG-Ida + Gemtuzumab Ozogamicin Regimen (Also known as FLAG-Ida + GO3x2) (AML19 Trial Course 1)
FLAG-Ida + Gemtuzumab Ozogamicin Regimen (Also known as FLAG-Ida + GO3x2) (AML19 Trial Course 1) AML19 Adults with Acute Myeloid Leukaemia or High-Risk Myelodysplastic Syndrome ***Refer to trial protocol
More informationTechnology appraisal guidance Published: 21 December 2016 nice.org.uk/guidance/ta425
Dasatinib, nilotinib and high-dose imatinib for treating imatinib-resistant or intolerant chronic myeloid leukaemia Technology appraisal guidance Published: 21 December 2016 nice.org.uk/guidance/ta425
More informationFull Trial Title: Adults with Acute Myeloid Leukaemia or High-Risk Myelodysplastic Syndrome (AML19) Approved by: Professor Nigel Russell Signature:
Full Trial Title: Adults with Acute Myeloid Leukaemia or High-Risk Myelodysplastic Syndrome (AML19) ISRCTN: ISRCTN78449203 EudraCT: 2014-002195-90 Approved by: Professor Nigel Russell Signature: Date:
More informationMS.4/ Acute Leukemia: AML. Abdallah Al Abbadi.MD.FRCP.FRCPath Feras Fararjeh MD
MS.4/ 27.02.2019 Acute Leukemia: AML Abdallah Al Abbadi.MD.FRCP.FRCPath Feras Fararjeh MD Case 9: Acute Leukemia 29 yr old lady complains of fever and painful gums for 1 week. She developed easy bruising
More informationThe Treatment of Adults with Acute Lymphoblastic Leukemia
ACUTE LYMPHOBLASTIC LEUKEMIA The Treatment of Adults with Acute Lymphoblastic Leukemia Adele Fielding 1 1 Royal Free and University College Medical School, London, UK Despite the relatively low incidence
More informationAcute Leukemia. Maureen Carr, MN, RN, AGPCNP-BC, AOCNP Hematology and Hematopoietic Cell Transplantation
Acute Leukemia Maureen Carr, MN, RN, AGPCNP-BC, AOCNP Hematology and Hematopoietic Cell Transplantation Disclosures Jazz Pharmaceuticals Speaker Bureau Acute myeloid leukemia (AML) Heterogeneous clonal
More informationAcute leukemia. Ibrahim Aldoss, MD Assistant Professor, City of Hope Hematology and Hematopoietic Cell Transplantation
Acute leukemia Ibrahim Aldoss, MD Assistant Professor, City of Hope Hematology and Hematopoietic Cell Transplantation Helocyte- Advisory board Acute myeloid leukemia (AML) Heterogeneous clonal malignancy
More informationPublished Ahead of Print on February 14, 2015, as doi: /haematol Copyright 2015 Ferrata Storti Foundation.
Published Ahead of Print on February 14, 2015, as doi:10.3324/haematol.2014.118588. Copyright 2015 Ferrata Storti Foundation. Final report of a phase II study of imatinib mesylate with hyper-cvad for the
More informationAxicabtagene ciloleucel IV for relapsed/refractory acute lymphoblastic leukaemia in children and adolecents (aged 2-21 years) second line
NIHR Innovation Observatory Evidence Briefing: August 2017 Axicabtagene ciloleucel IV for relapsed/refractory acute lymphoblastic leukaemia in children and adolecents (aged 2-21 years) second line NIHRIO
More informationWe are IntechOpen, the world s leading publisher of Open Access books Built by scientists, for scientists. International authors and editors
We are IntechOpen, the world s leading publisher of Open Access books Built by scientists, for scientists 3,500 108,000 1.7 M Open access books available International authors and editors Downloads Our
More informationSUPPLEMENTARY FILE GRAALL and GRAALL PROTOCOLS
SUPPLEMENTARY FILE GRAALL- 2003 and GRAALL- 2005 PROTOCOLS INTRODUCTION 1 FIGURE 1. GRAALL- 2003 AND GRAALL- 2005 OVERALL SURVIVAL 2 GRAALL- 2003 PROTOCOL 3 1. GENERAL STUDY DESIGN 3 2. INCLUSION AND NON-
More informationMUD SCT for Paediatric AML?
7 th South African Symposium on Haematopoietic Stem Cell Transplantation MUD SCT for Paediatric AML? Alan Davidson Haematology / Oncology Service Red Cross Children s Hospital THE SCENARIO A 10 year old
More informationGuideline on the use of minimal residual disease as a clinical endpoint in multiple myeloma studies
1 2 3 26 July 2018 EMA/CHMP/459559/2018 Committee for Medicinal Products for Human Use (CHMP) 4 5 6 Guideline on the use of minimal residual disease as a clinical endpoint in multiple Draft Draft agreed
More informationReduced-intensity Conditioning Transplantation
Reduced-intensity Conditioning Transplantation Current Role and Future Prospect He Huang M.D., Ph.D. Bone Marrow Transplantation Center The First Affiliated Hospital Zhejiang University School of Medicine,
More informationForm 2012 R3.0: Chronic Myelogenous Leukemia (CML) Pre-Infusion Data
Form 2012 R3.0: Chronic Myelogeus Leukemia (CML) Pre-Infusion Data Key Fields Sequence Number: Date Received: - - CIBMTR Center Number: CIBMTR Research ID: Event date: - - HCT type: (check all that apply)
More informationWhat is the optimal management strategy for younger CP-CML patients with matched, related donors who fail to achieve CCyR
What is the optimal management strategy for younger CP-CML patients with matched, related donors who fail to achieve CCyR after 18 months of imatinib? Second generation TKIs as a bridge to allogeneic SCT
More informationIndication for unrelated allo-sct in 1st CR AML
Indication for unrelated allo-sct in 1st CR AML It is time to say! Decision of allo-sct: factors to be considered Cytogenetic risk status Molecular genetics FLT3; NPM1, CEBPA. Response to induction Refractoriness
More informationRemission induction in acute myeloid leukemia
Int J Hematol (2012) 96:164 170 DOI 10.1007/s12185-012-1121-y PROGRESS IN HEMATOLOGY How to improve the outcome of adult acute myeloid leukemia? Remission induction in acute myeloid leukemia Eytan M. Stein
More informationDefinition of high risk disease for diffuse large B-cell lymphoma is score 4 or 5 based on the following risk factors:
INDICATION High grade lymphoma with high risk of CNS involvement Definition of high risk disease for diffuse large B-cell lymphoma is score 4 or 5 based on the following risk factors: Age > 60 Raised serum
More informationFACULTY TRAINING TRANSCRIPT
FACULTY TRAINING TRANSCRIPT PROGRAM CURRICULUM REVIEWED BY: B. DOUGLAS SMITH, MD Professor of Oncology Johns Hopkins University, School of Medicine Baltimore, MD JONATHAN WEBSTER, MD Instructor of Oncology
More informationJohann Hitzler, MD, FRCPC, FAAP Jacqueline Halton, MD, FRCPC Jason D. Pole, PhD
Photo by Tynan Studio Johann Hitzler, MD, FRCPC, FAAP Jacqueline Halton, MD, FRCPC Jason D. Pole, PhD 96 Atlas of Childhood Cancer in Ontario (1985-2004) Chapter 6: Leukemia 6 Leukemia Atlas of Childhood
More informationRecommended Timing for Transplant Consultation
REFERRAL GUIDELINES Recommended Timing for Transplant Consultation Published jointly by the National Marrow Donor Program /Be The Match and the American Society for Blood and Marrow Transplantation BeTheMatchClinical.org
More informationMaintenance rituximab following response to first-line therapy in mantle cell lymphoma
LONDON CANCER NEW DRUGS GROUP RAPID REVIEW Maintenance rituximab following response to first-line therapy in mantle cell lymphoma Maintenance rituximab following response to first-line therapy in mantle
More information